Synopsis
HCG built clinical expertise for cancer as well as good quality and technologically advanced hospitals. But it faltered on financial performance by going on a debt-funded expansion. CEO Raj Gore and his team set out to correct that, and the results are showing. HCG’s debt has come down and return ratios have started improving. Will it get stronger from here?
India’s burden of non-communicable diseases has been escalating and one of the key areas of concern is the growing incidence of cancer. Under-diagnosis, under-reporting, insufficient infrastructure, and limited awareness have exacerbated the problem.With the continuing rise in cancer cases, oncology is one of the fastest-growing segments in the Indian healthcare market. In FY19, the cancer-care market in the country was estimated at INR16,500
BY
ET Prime
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
-
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
link
More Stories
Stock and Share Market News, Economy and Finance News, Sensex, Nifty, Global Market, NSE, BSE Live IPO News
hcg shares: CVC Capital to buy cancer chain HCG for Rs 1,049 crore
Stocks to Watch Today, Sep 27: Infy, HealthCare Global, Century Tex, Suzlon